Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases [0.03%]
单基因预测与人工智能驱动的多基因精确诊疗在心血管疾病中的联合应用
Navakanth Raju Ramayanam,Sarad Pawar Naik Bukke,Chandrashekar Thalluri et al.
Navakanth Raju Ramayanam et al.
Pharmacogenomics (PGx) is transforming how we treat cardiovascular disease (CVD) by enabling us to select and dose drugs based on our genetic profiles. The pharmacokinetics and pharmacodynamics of commonly prescribed cardiovascular drugs ar...
Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care [0.03%]
儿科肿瘤学常规护理中实施预置型药物基因筛查的实践指南
Emma C Bernsen,Lidwien M Hanff,Theodorus W Kouwenberg et al.
Emma C Bernsen et al.
Interindividual variability in drug response is a challenge in pediatric oncology, where the risk of treatment-related toxicity is exacerbated by narrow therapeutic windows and combination therapies. Pharmacogenetics (PGx) aims to reduce th...
Reduction of next-generation sequencing files for efficient pharmacogenotype extraction [0.03%]
高效药物基因型提取的下一代测序文件精简
Hargoon N Kaur,Reynold C Ly,Steven M Bray et al.
Hargoon N Kaur et al.
Objectives: The most comprehensive computational pharmacogenotype extraction methods utilize Binary Alignment/Map (BAM) files, which require intensive storage resources. The pharmacogenotyping tool Aldy, which has been va...
Considerations for the clinical implementation of DPYD and UGT1A1-guided chemotherapy [0.03%]
DPYD和UGT1A1指导的化疗药物临床应用考量
Mary-Pearl Ojukwu,Carlos Vegas,Emily J Cicali et al.
Mary-Pearl Ojukwu et al.
Existing literature demonstrates the benefits of DPYD and UGT1A1 pharmacogenetic (PGx) testing to reduce toxicity from fluoropyrimidines and irinotecan, respectively. The Food and Drug Administration (FDA) has provided UGT1A1-guided irinote...
Genetics of tardive dyskinesia: a review of progress over the past decade [0.03%]
迟发性运动障碍的遗传学：过去十年的研究进展回顾
Clement C Zai,Megana Thamilselvan,Francesca Chernous et al.
Clement C Zai et al.
Tardive dyskinesia (TD) is a potentially irreversible movement disorder that emerges in a proportion of schizophrenia patients who are prescribed antipsychotic medications. These movements affect mostly the orofacial regions, but may also a...
Long non-coding RNAs and survival outcomes in chronic lymphocytic leukemia [0.03%]
长链非编码RNA与慢性淋巴细胞白血病预后的关系
Teodora Karan-Djurasevic,Irena Marjanovic,Natasa Tosic
Teodora Karan-Djurasevic
Chronic lymphocytic leukemia (CLL) is a highly heterogeneous hematological malignancy characterized by pronounced differences in clinical course and genetic background. While research has historically focused on alterations in protein-codin...
Jessica H Taylor,Hannah M Gunter,David W Haas et al.
Jessica H Taylor et al.
Advances in antiretroviral drug development have led to safer drugs with improved tolerability, enhanced activity against drug-resistant HIV, higher genetic barrier to resistance, and fewer drug-drug interactions. Genetic polymorphisms in d...
Prioritizing drugs for future clinical pharmacogenomics studies in Saudi Arabia: a generalizable multi-criteria framework [0.03%]
在沙特阿拉伯的未来临床药物基因组学研究中优先考虑药物：一个可推广的多标准框架
Mustafa Adnan Malki
Mustafa Adnan Malki
Aims: Despite over 400 high-evidence drug-gene associations in pharmacogenomic (PGx) guidelines and drug labels, prioritizing drugs for clinical PGx research remains challenging when local outcome data are limited. In Sau...
Pharmacogenetics of venlafaxine response in older adults with depression and chronic lower back pain [0.03%]
老年抑郁症和慢性下背痛患者对文拉法辛的药物基因组学研究
Martin Kronenbuerger,Leen Magarbeh,Stefan Kloiber et al.
Martin Kronenbuerger et al.
Background: Late-life depression (LLD) and chronic low back pain frequently co-occur and exacerbate one another. Outcomes with antidepressant treatment in this population are often suboptimal. Pharmacogenetic factors may ...
The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer [0.03%]
循环肿瘤DNA在转移性乳腺癌治疗选择中的作用
Oluwaferanmi Bello,Olivia Rieur,Neelima Vidula
Oluwaferanmi Bello
Metastatic breast cancer is a heterogeneous disease entity with varying genomic alterations. Mutations may be acquired through tumor evolution under the pressure of treatment. While both tumor tissue genotyping and cell-free DNA (cfDNA)/cir...